Industry veteran appointed

Industry veteran Dieter Weinand has joined the Board of Directors of Sibylla Biotech. He brings many years of experience in the pharmaceutical industry, including leading business units and drug commercialisation initiatives in global companies. Most recently, he led the Global Primary Care Business at Sanofi, where he optimised the company’s portfolios. As President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG, he oversaw the integration of R&D, manufacturing and all commercial and support functions for the Healthcare Division and implemented key growth strategies. He has also held key leadership positions at Bristol-Myers Squibb and Pfizer. He is Chairman of the Board of Confo Therapeutics, DISCO Pharmaceuticals and FORE Biotherapeutics. He is also Lead Independent Director at Replimune (Nasdaq: REPL) and a board member at Coya Therapeutics (Nasdaq: COYA).

“Having an industry leader of Dieter’s stature head our Board underscores the potential of Sibylla’s technology to reshape the drug discovery landscape by unlocking access to a range of previously undruggable targets. Dieter’s demonstrated success in driving value from R&D to the commercialization of impactful medicines will guide the next stages of Sibylla’s growth as we advance our pipeline of folding interference small molecules in preclinical studies. Personally, I will be honored to have him at our side,” said Lidia Pieri, PhD, MBA, Co-Founder and Chief Executive Officer of Sibylla Biotech.